KalVista Pharmaceuticals Shares Sebetralstat Data at 2024 HAEi Forum
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced that it presented data demonstrating the effectiveness of sebetralstat in reducing anxiety during hereditary angioedema (HAE) attacks at the HAEi Global Angioedema Forum (GAF)…
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Rule 5635(C)(4)
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on innovative treatments for neurological diseases, announced the granting of inducement awards to three new employees. The Board’s Compensation Committee…
Kezar Life Sciences Puts Zetomipzomib IND for Lupus Nephritis on Clinical Hold
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology firm focused on developing innovative small molecules for immune-mediated diseases, has announced that its Investigational New Drug (IND) application for zetomipzomib,…
First Patient Enrolled in Phase I/IIa Trial for Lenti-HPV-07 Vaccine Against HPV-Induced Cancers
TheraVectys, a biotechnology firm focused on creating lentiviral vector-based vaccines and immunotherapies for infectious diseases and cancers, has announced the enrollment of the first patient in a Phase I/IIa clinical…
Medical Alert Monitoring Association Conference Highlights Innovations in Remote Care for Seniors
The Medical Alert Monitoring Association (MAMA) recently wrapped up its annual conference in Washington D.C. on September 24 and 25. The event gathered industry leaders, healthcare professionals, and advocates dedicated…
A2 Bio to Present EVEREST-1 Trial Data at SITC 2024
A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company focused on developing first-in-class logic-gated cell therapies to selectively target tumor cells while protecting healthy cells, has announced that six…
Study Shows Kerecis Fish-Skin Outperforms in Diabetic Foot Ulcer Treatment
Kerecis, a leader in the use of fish skin and fatty acids for tissue regeneration, has announced the publication of significant study results in the New England Journal of Medicine…
Aulos Bioscience to Present Phase 2 Data for AU-007 at SITC Annual Meeting
Aulos Bioscience, an immuno-oncology company focused on advancing cancer care through innovative IL-2 therapeutics, has announced the presentation of encouraging safety and efficacy data from the Phase 2 dose expansion…
Peak Mobile Vascular Expands to the Midwest
Peak Mobile Vascular Access is expanding its services to the Midwest, aiming to offer its exceptional vascular access solutions—such as PICC lines, Midlines, and Peripheral IVs—to a wider audience. This…
FDA Approves Exact Sciences’ Cologuard Plus for Colorectal Cancer Screening
Exact Sciences Corp. (NASDAQ: EXAS), a prominent provider of cancer screening and diagnostic solutions, has announced that the U.S. Food and Drug Administration (FDA) has approved its next-generation multitarget stool…
Summit Therapeutics Completes Enrollment in Phase III HARMONi Trial for 2L+ EGFRm NSCLC
Summit Therapeutics Inc. (NASDAQ: SMMT) has announced the completion of patient enrollment in its HARMONi clinical trial. This multi-regional Phase III study evaluates ivonescimab combined with platinum-doublet chemotherapy versus placebo…
FDA Approves Neoadjuvant Opdivo® and Chemotherapy for Resectable Non-Small Cell Lung Cancer
Bristol Myers Squibb (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved Opdivo® (nivolumab) for adult patients with resectable non-small cell lung cancer (NSCLC) with…